8-K: Adaptimmune Therapeutics Amends Severance Agreement with CFO Gavin Wood, Extending Employment to August 2025

Adaptimmune Therapeutics has amended its severance agreement with CFO Gavin Wood, extending his employment until August 31, 2025, due to redundancy.

Summary

• Adaptimmune Therapeutics plc has amended its letter agreement with Gavin Wood, the Chief Financial Officer, regarding the termination of his employment.
• The original agreement, dated December 18, 2024, outlined Mr. Wood's termination on May 31, 2025, due to redundancy.
• The amended agreement, dated April 14, 2025, extends Mr. Wood's employment with Adaptimmune Limited until August 31, 2025, which is referred to as the Revised Termination Date.
• Mr. Wood's severance terms are governed by the company's Executive Severance Policy dated March 10, 2017, as amended.
• These terms include a severance payment equal to 12 months of his 2025 base salary, eligibility for a pro-rata bonus for 2025 at the discretion of the Remuneration Committee, and reimbursement of healthcare benefits for 12 months following the Revised Termination Date or a payment equal to their value.
• All payments will be subject to applicable tax deductions.
• Market value options covering ordinary shares granted to Mr. Wood will continue to vest until the Revised Termination Date, subject to the relevant Plan rules and vesting schedules.
• Mr. Wood will have 12 months from the Revised Termination Date to exercise the Market Value Options that have vested by that date.
• All other provisions in the original letter agreement will continue to apply.
• Obligations in the Service Agreement which are expressed to survive the termination of employment, including clauses 15, 17, 18, and 22 shall remain in full force and effect after the Termination Date, unless otherwise agreed in writing.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing an administrative change. The extension of employment could be seen as slightly positive for stability, but the underlying reason is redundancy, which tempers the overall sentiment.

Positives

• The extension of employment provides continuity during a transition period.
• Mr. Wood remains eligible for a pro-rata bonus, incentivizing continued performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance or guidance.

Management Comments

• Adrian Rawcliffe, Chief Executive Officer of Adaptimmune Therapeutics plc, signed the variation letter agreement.

Industry Context

Executive departures and transitions are common in the biotechnology industry, especially during periods of restructuring or strategic shifts. This amendment provides a more extended transition period for the CFO role.

Comparison to Industry Standards

• Severance packages in the biotech industry typically include a base salary continuation, bonus eligibility, and benefits continuation, which aligns with the terms provided to Mr. Wood.
• Companies like Gilead Sciences, Amgen, and Biogen often provide similar severance terms to their executives, depending on the circumstances of their departure.
• The 12-month period for exercising vested stock options is also a fairly standard practice in executive severance agreements.

Management Changes

Stakeholder Impact

• Shareholders may view the extended employment as providing stability during the transition.
• Employees may be affected by the redundancy decision, potentially leading to uncertainty.
• The company's creditors and suppliers may experience minimal impact from this executive change.

Key Dates

Keywords

severance, Gavin Wood, CFO, Adaptimmune Therapeutics, termination, redundancy, employment agreement, share options